Details for New Drug Application (NDA): 206916

NDA 206916 describes PALONOSETRON HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Rx, Cipla, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Meitheal, Mylan Institutional, Novast Labs, Qilu Pharm Hainan, Sagent Pharms Inc, Sandoz, Teva Pharms Usa, and Hikma, and is included in twenty NDAs. It is available from twenty suppliers. Additional details are available on the PALONOSETRON HYDROCHLORIDE profile page.

The generic ingredient in PALONOSETRON HYDROCHLORIDE is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the palonosetron hydrochloride profile page.

Summary for 206916

Tradename:	PALONOSETRON HYDROCHLORIDE
Applicant:	Baxter Hlthcare Corp
Ingredient:	palonosetron hydrochloride
Patents:	0

Pharmacology for NDA: 206916

Mechanism of Action

Serotonin 3 Receptor Antagonists

Suppliers and Packaging for NDA: 206916

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	206916	ANDA	Baxter Healthcare Corporation	36000-326	36000-326-02	1 VIAL in 1 CARTON (36000-326-02) / 5 mL in 1 VIAL (36000-326-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
Approval Date:	Nov 12, 2021	TE:	AP	RLD:	No

Complete Access Available with Subscription